Horizon: Phase 2 Trial With Dazodalibep Meets Primary Endpoints In Both Patient Populations
18/1 14:37
(RTTNews) - Horizon Therapeutics plc (HZNP) announced that the primary endpoint was met for the second population in its Phase 2 clinical trial evaluating dazodalibep for the treatment of Sjgren's syndrome. The positive results in the first patient population were announced in Se...